Allergan Declares ACHIEVE II Trial Results for Ubrogepant – An AntiMigraine Tablet

0
460

Allergan plc declared results from its ACHIEVE II clinical trial study aimed at analyzing different properties of anti-migraine medicine, Ubrogepant. The pivotal phase 3 trial results appear online in the Journal of the American Medical Association – JAMA. Scientists from Montefiore Headache Center took part in the study.

The results encouraged the acute management of migraine with the medicine in comparison to placebo decreased pain to a more significant extent.

The uptake was timed at two hours with two doses of 50 mg and 25 mg, and results proved positive for the 50 mg with riddance from the troublesome pain associated with migraines. On its approval, Ubrogepant will be the first authenticated form of oral medication for the treatment of migraines on an acute level.

Ubrogepant is a calcitonin gene-related peptide receptor antagonist in the form of oral medication for migraine treatment.

According to statistics, Migraine is the second most common cause of disability, and people need acute treatments for this condition which are efficient, tolerable, and safe. Ubrogepant being the potential medication prescribed for the acute treatment of migraine will bring a wave of innovation for all people having this highly dangerous disease.

The trial analyzed the medication for the doses 50 mg and 25 mg in comparison to the placebo, across a variety of clinical stages. It also included the existing primary endpoints from the absence of pain as well as the presence of no bothersome symptoms associated with migraines two hours after the first initial dosage.

For the two endpoints at primary levels, the medication for the different dosages 50 mg and 25 mg statistically depicted significantly higher response rates for the absence of pain in two hours and the higher dosage of the medication depicted that significantly better response rates for the absence of troublesome symptoms associated with a migraine after two hours.

The studies for the medication depict that both dosages – 50 mg and 25 mg were easily taken up having adverse event profile alike placebo. The most usual side effect of the single stack researches that occurred with an incidence of more than 2 percent and generally twice the placebo rate was nausea.

The incidence of this adverse reaction was 2 to 4 percent. In an extensive study that went for more than a year, the highly common adverse event related to the disease was nausea as well as having an incidence of less than 2 percent.

On the approval, the medication ubrogepant will be offering a better and effective treatment option for acute migraine patients going through excruciating pain and relevant migraine symptoms. Allergan has a long developmental history of migraine medications and is adamant in paving way for more medications for better treatments.

There is a belief that multiple treatment options are available as not all patients will be responding to all kinds of medications. We also believe that patients must have access to all types of treatments for the disease.

With more advancements in the research related to countering the acute migraine in patients with troublesome symptoms, there will be more chances for effective and less reactive medications like ubrogepant to grow.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here